Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2019

View Archived Issues

In seizures ER stress is best bad option

BlueWillow Biologics receives support to develop peanut allergy vaccine

Sabin Vaccine Institute granted BARDA funding to develop Ebola Sudan and Marburg vaccines

Phase I study of CSL-200 gene therapy in adults with severe sickle cell disease

First patient dosed in global phase III pivotal study of zilucoplan for gMG

Promising preclinical data presented for EmtinB glaucoma program

Recruitment ongoing in phase I/II study of IMSA-101 in refractory malignancies

Preliminary data presented for patients with mTNBC enrolled in PIVOT-02 study

Circulating total leptin as a diagnostic and prognostic biomarker in critically ill septic patients

Death receptor 5 as novel biomarker in acute respiratory distress syndrome

CPC-634 shows prolonged higher systemic and intratumoral docetaxel exposure

Vulnerabilities exploited for liver cancer treatment

Shanghai HaiHe Biopharma, Shanghai Institute of Materia Medica patent mutant EZH2 inhibitors

US Department of Health & Human Services and collaborators describe D1 receptor PAMs

IOCB Prague and Univerzita Palackeho v Olomouci disclose nucleoside derivatives

Discovery of novel small-molecule inhibitor of PWWP1 domain of NSD3 for acute myeloid leukemia

Biomica begins preclinical studies with microbial consortia BMC-321 and BMC-322 for IBD

Adynxx receives funding award to develop nonopioid chronic pain product candidate

New GABRA5 inverse agonists discovered at Shanghai SIMR Biotech

Shanghai Allist Pharmaceutical describes new PARP inhibitors

XBiotech initiates phase II study of bermekimab in systemic sclerosis

Phase III THEMIS-PCI results on ticagrelor published

Actinogen reports cognition data on Xanamem in healthy elderly subjects

Phase II data show efficacy of TTP-399 as an adjunctive therapy for type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.